<DOC>
	<DOC>NCT00662805</DOC>
	<brief_summary>Primary objective: Evaluation of the safety of Seretide discus administration in subjects with COPD. Treatment duration: 2 years. Study has 3 phases: Screening phase (visit 1), treatment phase (visits 2-5. In the case of AE, there will be another visit (visit 6) as a follow up visit - follow up phase.</brief_summary>
	<brief_title>Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Subject should fulfill criteria for the subscription of SERETIDE as these are mentioned in SPC. Hypersensitivity to Salmeterol + Fluticasone or any of its excipients Pregnancy, lactation or scheduled pregnancy during the observational period of the study Serious illness/disease, not adequately controlled, or with a potential to interfere with the patients' participation in the present study, according to the investigator/physician's judgment.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>pharmacovigilance</keyword>
	<keyword>COPD</keyword>
</DOC>